Skip to content

Mindfulness-Based Stress Reduction Alleviates Depression, Anxiety, and Internalized Stigma Compared With Treatment-as-Usual Among Head and Neck Cancer Patients: Findings From a Randomized Controlled Trial.

Zheng Zhang, Qingqin Zhang, Ping Lu, Nurul Izzah Shari, Nik Ruzyanei Nik Jaafar, Mohd Razif Mohamad Yunus, Qiyue Qiu, Fuad Ismail, Nor Faizah Ab Muin, Mohammad Farris Iman Leong Bin Abdullah

Depression and Anxiety September 11, 2025 DOI: 10.1155/da/7499120 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Double-blind Peer reviewed
Sample size 110
Population Head and neck cancer patients
Intervention Mindfulness-based stress reduction (MBSR)
Duration 8-week intervention; follow-up assessment 12 weeks after intervention completion
Topics Anxiety Depression Meditation
Keywords Humans Double-blind method Stress, psychological Adult Middle aged Female Social stigma Rct Internalized stigma
Registration NCT06991309
Key findings MBSR significantly reduced depression and anxiety symptom severity and internalized stigma and its components across three timepoints, while the treatment-as-usual group showed no reduction. Internalized stigma, shame with appearance, and speech and social concerns partially mediated the relationship between MBSR and depression and anxiety severity. The authors conclude MBSR could be recommended as part of the treatment regimen for head and neck cancer patients.

Abstract

Background: This study aimed to: (1) compare the rates of change in the severity of depression and anxiety symptoms (primary outcomes) as well as internalized stigma and its components (shame with appearance [SWA], speech and social concerns [SSCs], sense of stigma [SS], and regret [R]; secondary outcomes) between the mindfulness-based stress reduction (MBSR) group and the treatment-as-usual (TAU) control group across three timepoints (T 0 = baseline assessment, prior to intervention; T 1 = postintervention, immediately after completion of intervention or at 8 weeks after commence of intervention; T 2 = follow-up assessment, 12 weeks after completion of intervention), and (2) evaluate the mediating effects of reductions in internalized stigma and its components on the relationship between MBSR and the severity of depression and anxiety symptoms among head and neck cancer (HNC) patients.

Methods: This multicenter, two-armed, parallel, and double-blind randomized controlled trial (RCT) recruited 110 HNC patients. All participants were assessed for the severity of depression and anxiety symptoms, and the degrees of internalized stigma and its components, at each timepoint.

Results: MBSR significantly reduced the severity of depression and anxiety symptoms and degrees of internalized stigma and its components across timepoints (T 0, T 1, and T 2). In contrast, no reduction in scores was observed in the TAU group. Furthermore, internalized stigma, SWA, and SSC partially mediated the relationship between MBSR and the severity of depression and anxiety symptoms. Sensitivity analyses confirmed that the changes in the severity of depression and anxiety symptoms and degrees of internalized stigma and its components according to intention-to-treat (ITT) analysis were similar to that of per-protocol (PP) and last observation carry forward (LOCF) analyses.

Conclusion: MBSR could be recommended as part of the treatment regimen for HNC patients.

Trial Registration: ClinicalTrials.gov identifier: NCT06991309.

Comparable studies

Other randomized controlled trials on anxiety, most cited first.

Study Year Design Participants
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Adults with advanced-stage cancer and anxiety 2010 Double-blind, placebo-controlled study n = 12

Citations in the library

Explore topics